This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Nordic Bioscience | |
|---|---|
| Name | Nordic Bioscience |
| Type | Private |
| Industry | Biotechnology |
| Founded | 1987 |
| Headquarters | Herlev, Denmark |
| Products | Biomarker assays, diagnostic kits, research services |
Nordic Bioscience Nordic Bioscience is a Danish biotechnology company specializing in biomarker discovery, assay development, and clinical biomarker services. Founded in the late 20th century, the company operates from Herlev and engages with pharmaceutical firms, academic institutions, and regulatory bodies across Europe and North America. Nordic Bioscience collaborates with research hospitals, contract research organizations, and university research centers to support translational research and drug development.
Nordic Bioscience was established during a period of rapid expansion in the biotechnology sector alongside contemporaries such as Genentech, Amgen, Biogen, Roche, and Novartis. Early ties connected the company with Danish research institutions including University of Copenhagen, Aarhus University, Rigshospitalet, and Karolinska Institutet. Over time, Nordic Bioscience developed partnerships with multinational firms like Pfizer, GlaxoSmithKline, Sanofi, Eli Lilly and Company, and Bayer, while engaging in funded projects with entities such as the European Commission, Innovative Medicines Initiative, Copenhagen Capacity, and national innovation agencies. The firm navigated industry milestones including the rise of precision medicine epitomized by initiatives from National Institutes of Health, European Medicines Agency, and consortia such as Translational Medicine networks. Leadership changes echoed patterns seen at companies like Novo Nordisk and LEO Pharma, and the company weathered financial cycles comparable to those experienced by Thermo Fisher Scientific and Illumina.
Nordic Bioscience focuses R&D on extracellular matrix biomarkers, collagen turnover, and protein degradation similar to research programs at Harvard Medical School, Stanford University, Massachusetts Institute of Technology, and University College London. Their laboratories implement technologies related to enzyme-linked immunosorbent assay methods used at institutions like Salk Institute, and mass spectrometry strategies common to Max Planck Society and EMBL. Collaborative projects have linked Nordic Bioscience with disease-focused centers such as Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, and Karolinska University Hospital to study conditions including osteoarthritis, rheumatoid arthritis, fibrosis, and oncology, reflecting research themes pursued at Memorial Sloan Kettering Cancer Center and Fred Hutchinson Cancer Center. Methodological work references standards from organizations like Clinical and Laboratory Standards Institute, and aligns with biomarker qualification frameworks promoted by FDA and European Medicines Agency initiatives.
The company offers biomarker assays, kit development, biomarker validation, and laboratory services akin to offerings from Quanterix, Myriad Genetics, Bio-Rad Laboratories, Thermo Fisher Scientific, and PerkinElmer. Nordic Bioscience provides contract research services to pharmaceutical sponsors comparable to Charles River Laboratories and Covance and supplies data to clinical groups at Uppsala University Hospital, St Thomas' Hospital, and Guy's and St Thomas' NHS Foundation Trust. Product lines address musculoskeletal and fibrotic diseases that are also central to research programs at Boston Children's Hospital and Hospital for Special Surgery. The firm’s assay catalog often complements biomarker repositories maintained by institutions such as Wellcome Trust and biobanks like UK Biobank and Danish National Biobank.
Nordic Bioscience participates in clinical biomarker studies and collaborates with contract research organizations and academic consortia, traveling alongside trials organized by ICON plc, PPD (Thermo Fisher) and networks like EATRIS and IMI. The company has been involved in investigator-initiated studies at centers such as Charité – Universitätsmedizin Berlin, Hôpital Pitié-Salpêtrière, Karolinska University Hospital, and Rigshospitalet. Collaborative clinical programs have intersected with therapeutic developers including AstraZeneca, Johnson & Johnson, Merck & Co., and Bristol Myers Squibb, and with disease consortia like Osteoarthritis Research Society International and American College of Rheumatology. Trial activities conform to protocols influenced by guidelines from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and reporting frameworks echoed in publications from The Lancet and New England Journal of Medicine.
Nordic Bioscience maintains quality systems aligned with standards implemented by International Organization for Standardization (ISO) and regulatory expectations from European Medicines Agency and U.S. Food and Drug Administration. Laboratory accreditation efforts reflect models at College of American Pathologists and certification pathways similar to ISO 13485 and ISO 15189. The company’s regulatory interactions mirror practices used by biotech peers during submissions to agencies like FDA, Medicines and Healthcare products Regulatory Agency, and regional health authorities in Denmark and Sweden. Data handling and clinical study conduct adhere to frameworks comparable to Good Clinical Practice and data standards promoted by CDISC.
Nordic Bioscience is privately held and has structured its governance with a board and executive management reflective of corporate models at Novo Nordisk Foundation, Carlsberg Group, and listed peers such as Novo Nordisk A/S and Coloplast. The company has engaged in strategic partnerships and equity arrangements similar to transactions involving Hansen Family, Wellington Management, and corporate investors like Novo Holdings. Operational hubs draw talent from academic clusters at University of Copenhagen, Aarhus University, and Technical University of Denmark, and maintain professional services relationships comparable to those with firms like Deloitte, PwC, and KPMG.
Nordic Bioscience has received industry recognition and participated in forums alongside winners from European Business Awards, Danish Growth Fund initiatives, and biotech competitions involving organizations such as Innovation Fund Denmark and Venture Cup. The company’s scientific output has been cited in journals and conference proceedings similar to those of Nature Medicine, Science Translational Medicine, Annals of the Rheumatic Diseases, and presentations at meetings like the American College of Rheumatology annual meeting, European League Against Rheumatism congress, and American Thoracic Society International Conference.
Category:Biotechnology companies of Denmark